GNL Gut and Liver
  1. Yuting Guo, Juan Chen, Nan Liu, Zheng Liu, Bimin Shi, Hong Sun. Association of Circulating TXNIP Levels with Fatty Liver in Newly Diagnosed Type 2 Diabetes Mellitus. DMSO 2022;Volume 15:225
    https://doi.org/10.2147/DMSO.S349153
  2. Ilias D. Vachliotis, Ioannis Valsamidis, Stergios A. Polyzos. Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. Cancers 2023;15:5306
    https://doi.org/10.3390/cancers15215306
  3. Daniel Taranto, Daan J. Kloosterman, Leila Akkari. Macrophages and T cells in metabolic disorder-associated cancers. Nat Rev Cancer 2024;24:744
    https://doi.org/10.1038/s41568-024-00743-1
  4. Satoshi Shinozaki, Toshiyuki Tahara, Kouichi Miura, Alan Kawarai Lefor, Hironori Yamamoto. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study. Life 2023;13:1327
    https://doi.org/10.3390/life13061327
  5. Li Chen, Qin Chen, Xueping Chen, Pengli Zhu, Meinan Chen, Wei Wang, Shandong Ye, Mao Zheng. Clinical Application of Metformin Use in Anhui Province, China: A Cross-Sectional Study. JMDH 2023;Volume 16:345
    https://doi.org/10.2147/JMDH.S397061
  6. Mingxiao Luo, Tingting Li, Haiquan Sang. The role of hypoxia-inducible factor 1α in hepatic lipid metabolism. J Mol Med 2023;101:487
    https://doi.org/10.1007/s00109-023-02308-5
  7. Milena Vesković, Nikola Šutulović, Dragan Hrnčić, Olivera Stanojlović, Djuro Macut, Dušan Mladenović. The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach. CIMB 2023;45:9084
    https://doi.org/10.3390/cimb45110570
  8. Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Hebatallah M. Saad, Gaber El-Saber Batiha. The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM). Inflammopharmacol 2023;31:1751
    https://doi.org/10.1007/s10787-023-01255-4
  9. Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui, Jinjun Guo. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol. 2023;13
    https://doi.org/10.3389/fendo.2022.1087260
  10. Nermeen Bastawy, Ghada Farouk Soliman, Nermeen Bakr Sadek, Doaa Mostafa Gharib, Mai Abdelaziz Gouda, Laila Ahmed Rashed, Hanan Abdallah, Dina Hisham, Omnia Mohamed Abdel-Maksoud. Metformin and intermittent fasting mitigate high fat-fructose diet-induced liver and skeletal muscle injury through upregulation of mitophagy genes in rats. Beni-Suef Univ J Basic Appl Sci 2024;13
    https://doi.org/10.1186/s43088-024-00548-z
  11. André J. Scheen. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD). Diabetes Epidemiology and Management 2023;11:100145
    https://doi.org/10.1016/j.deman.2023.100145
  12. Roman Abrosimov, Marius W. Baeken, Samuel Hauf, Ilka Wittig, Parvana Hajieva, Carmen E. Perrone, Bernd Moosmann. Mitochondrial complex I inhibition triggers NAD+-independent glucose oxidation via successive NADPH formation, “futile” fatty acid cycling, and FADH2 oxidation. GeroScience 2024;46:3635
    https://doi.org/10.1007/s11357-023-01059-y
  13. Sarvesh Sabarathinam, Ramesh Venkatachalapathy, Akash Jayaraman. Metformin's modulation of gut microbiota and its implications for Non-Alcoholic Fatty Liver Disease(NAFLD): A network pharmacology and molecular dynamics study. Human Gene 2025;43:201364
    https://doi.org/10.1016/j.humgen.2024.201364
  14. Ayda Esmaeili, Reza Pourahmad Azar, Mohammadreza Mohammad Hosseiniazar, Laya Hooshmand Gharabagh. Empagliflozin add‐on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open‐label, single‐center, pilot clinical trial. J of Gen and Family Med 2024;25:351
    https://doi.org/10.1002/jgf2.723
  15. Janina Senn, Stefan Fischli. Visceral and Ectopic Fat. 2024.
    https://doi.org/10.1016/B978-0-12-822186-0.00014-6
  16. Ricardo Amorim, Pedro Soares, Daniel Chavarria, Sofia Benfeito, Fernando Cagide, José Teixeira, Paulo J. Oliveira, Fernanda Borges. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities. European Journal of Medicinal Chemistry 2024;277:116723
    https://doi.org/10.1016/j.ejmech.2024.116723
  17. Alessandro Mantovani, Amedeo Lonardo, Norbert Stefan, Giovanni Targher. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers. Metabolism 2024;160:156014
    https://doi.org/10.1016/j.metabol.2024.156014
  18. Athreya Steiger, Nathan T. VanderVeen, Esther H. Kang, Amy K. Weimer. Resolution of metabolic dysfunction‐associated steatohepatitis with estradiol in a transgender female: A case report. JPGN rep. 2024;5:223
    https://doi.org/10.1002/jpr3.12054
  19. Rahnuma Ahmad, Mainul Haque. Metformin: Beyond Type 2 Diabetes Mellitus. 2024
    https://doi.org/10.7759/cureus.71730
  20. Mohamed Abouelkheir, Ibrahim Taher, Amira S. R. Eladl, Dalia A. Shabaan, Mona F. M. Soliman, Ahmed E. Taha. Detection and Quantification of Some Ethanol-Producing Bacterial Strains in the Gut of Mouse Model of Non-Alcoholic Fatty Liver Disease: Role of Metformin. Pharmaceuticals 2023;16:658
    https://doi.org/10.3390/ph16050658
  21. Hyeonji Kim, Kippeum Lee, Ju-Yeon Kim, Jae-Jung Shim, Junghyun Lim, Joo-Yun Kim, Jung-Lyoul Lee. Lactobacillus helveticus Isolated from Raw Milk Improves Liver Function, Hepatic Steatosis, and Lipid Metabolism in Non-Alcoholic Fatty Liver Disease Mouse Model. Microorganisms 2023;11:2466
    https://doi.org/10.3390/microorganisms11102466
  22. Bodil Bjørndal, Tra-My Thi Le, Elin Strand, Lise Madsen, Rolf K. Berge. Metformin Lowers Plasma Triacylglycerol Levels in Mice with Impaired Carnitine Biosynthesis and Fatty Liver. SynBio 2024;2:240
    https://doi.org/10.3390/synbio2030014
  23. Jose Arriola-Montenegro, Renato Beas, Renato Cerna-Viacava, Andres Chaponan-Lavalle, Karla Hernandez Randich, Diego Chambergo-Michilot, Herson Flores Sanga, Pornthira Mutirangura. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World J Cardiol 2023;15:328
    https://doi.org/10.4330/wjc.v15.i7.328
  24. Nataša Milošević, Maja Milanović, Milica Medić Stojanoska, Varomyalin Tipmanee, Ilias Smyrnioudis, George V. Dedoussis, Nataša Milić. Triterpenoids from Chios Mastiha Resin Against MASLD—A Molecular Docking Survey. CIMB 2025;47:51
    https://doi.org/10.3390/cimb47010051
  25. Amin Hasanvand. The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases. Inflammopharmacol 2022;30:775
    https://doi.org/10.1007/s10787-022-00980-6
  26. Hang Chen, Minshan Huang, Dan Zhang, Hui Wang, Da Wang, Mengwei Li, Xianmei Wang, Rui Zhu, Jianjun Liu, Lanqing Ma. Metformin’s effect on metabolic dysfunction-associated steatotic liver disease through the miR-200a-5p and AMPK/SERCA2b pathway. Front. Pharmacol. 2024;15
    https://doi.org/10.3389/fphar.2024.1477212
  27. Sadra Samavarchi Tehrani, Golnaz Goodarzi, Ghodratollah Panahi, Fahimeh Zamani-Garmsiri, Reza Meshkani. The combination of metformin with morin alleviates hepatic steatosis via modulating hepatic lipid metabolism, hepatic inflammation, brown adipose tissue thermogenesis, and white adipose tissue browning in high-fat diet-fed mice. Life Sciences 2023;323:121706
    https://doi.org/10.1016/j.lfs.2023.121706
  28. Sora Kwon, Reshani Jeyaratnam, Kyoung-Han Kim. Targeting ketone body metabolism to treat fatty liver disease. J. pharm. pharm. sci. 2024;27
    https://doi.org/10.3389/jpps.2024.13375
  29. Zhenzhen Fang, Gang Shen, Yina Wang, Fuyan Hong, Xiumei Tang, Yongcheng Zeng, Ting Zhang, Huanyi Liu, Yanmei Li, Jinhong Wang, Jing Zhang, Anton Gao, Weiwei Qi, Xia Yang, Ti Zhou, Guoquan Gao. Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease. Sig Transduct Target Ther 2024;9
    https://doi.org/10.1038/s41392-024-01781-9
  30. Iryna Halabitska, Pavlo Petakh, Oleh Lushchak, Iryna Kamyshna, Valentyn Oksenych, Oleksandr Kamyshnyi. Metformin in Antiviral Therapy: Evidence and Perspectives. Viruses 2024;16:1938
    https://doi.org/10.3390/v16121938
  31. Inhye Kim, Mi-lang Kyun, Hyewon Jung, Ji-In Kwon, Jeongha Kim, Ju-Kang Kim, Yu Bin Lee, Young-In Kwon, Kyoung-Sik Moon. In Vitro Nonalcoholic Fatty Liver Disease Model Elucidating the Effect of Immune Environment on Disease Progression and Alleviation. ACS Omega 2024;9:25094
    https://doi.org/10.1021/acsomega.4c02433
  32. Nutan Sharma, Lakhwinder Singh, Aditya Sharma, Ajay Kumar, Dinesh Mahajan. NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors. Pharmacological Research 2024;208:107375
    https://doi.org/10.1016/j.phrs.2024.107375
  33. Jabeur Methnani, Marwa Hajbelgacem, Taieb Ach, Faten Chaieb, Sana Sellami, Ali Bouslama, Monia Zaouali, Asma Omezzine, Ezdine Bouhlel. Effect of Pre-Meal Metformin With or Without an Acute Exercise Bout on Postprandial Lipemic and Glycemic Responses in Metabolic Syndrome Patients: A Randomized, Open Label, Crossover Study. J Cardiovasc Pharmacol Ther 2023;28
    https://doi.org/10.1177/10742484231156318
  34. A. S. Teplova, T. L. Bogacheva, A. E. Timofeeva, D. S. Stegacheva. 70 years of metformin use. Success and achievements. jour 2024;5:62
    https://doi.org/10.62751/2713-0177-2024-5-2-19
  35. Joonpyo Lee, Mi-Seung Shin. Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management. CPP 2025;7:1
    https://doi.org/10.36011/cpp.2025.7.e2
  36. Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Domenico Triggiani, Rossella Donghia, Lucilla Crudele, Roberta Rinaldi, Carlo Sabbà, Vincenzo Triggiani, Giovanni De Pergola, Giuseppina Piazzolla. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients 2022;14:4673
    https://doi.org/10.3390/nu14214673
  37. Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel. Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments. World J Gastroenterol 2023;29:4831
    https://doi.org/10.3748/wjg.v29.i32.4831
  38. Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Majid S. Jabir, Salim Albukhaty. Effects of metformin on fibroblast growth factor 21 in patients with type 2 diabetes mellitus: faraway but so close. Egypt J Intern Med 2023;35
    https://doi.org/10.1186/s43162-023-00238-9
  39. Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023;59:1789
    https://doi.org/10.3390/medicina59101789
  40. Qiuyu Xu, Jie Zhang, Yan Lu, Ling Wu. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome. iScience 2024;27:108783
    https://doi.org/10.1016/j.isci.2024.108783
  41. Hongjuan Fu, Jianbo He, Cong Li, Hui Chang. Theaflavin-3,3'-Digallate Protects Liver and Kidney Functions in Diabetic Rats by Up-Regulating Circ-ITCH and Nrf2 Signaling Pathway. J. Agric. Food Chem. 2024;72:14630
    https://doi.org/10.1021/acs.jafc.3c08251
  42. Hyeon-Ji Kim, Hye-Jin Jeon, Dong-Gun Kim, Joo-Yun Kim, Jae-Jung Shim, Jae-Hwan Lee. Lacticaseibacillus paracsei HY7207 Alleviates Hepatic Steatosis, Inflammation, and Liver Fibrosis in Mice with Non-Alcoholic Fatty Liver Disease. IJMS 2024;25:9870
    https://doi.org/10.3390/ijms25189870
  43. Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi, Theodoros Androutsakos. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. Eur J Clin Pharmacol 2024;80:127
    https://doi.org/10.1007/s00228-023-03586-1
  44. Zara Siu Wa Chui, Yaqian Xue, Aimin Xu. Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease. 2024;4:158
    https://doi.org/10.1515/mr-2024-0007
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd